Scandius BioMedical's Stratis (TM) ST ACL Reconstruction System launched and successfully used in initial surgeries

Company's technology designed for simplicity achieves

consistent and reliable results for Orthopedic Surgeons

Jan 12, 2005, 00:00 ET from Scandius BioMedical, Inc.

    LITTLETON, Mass., Jan. 12 /PRNewswire/ -- Scandius BioMedical, Inc.
 announced today that the Stratis ST ACL Reconstruction System and Femoral
 Fixation Implant have been launched and successfully used in its initial
 surgeries since its recent FDA market clearance.   The Stratis ST system is
 used by orthopedic surgeons to repair the single most common sports-related
 orthopedic joint injury -- the reconstruction of the torn ACL (Anterior
 Cruciate Ligament).  The Stratis ST System and Implant couples ease of use
 with secure fixation yielding consistent and reliable reconstruction.
     "In surgery, use of the Stratis ST System simplified and expedited our
 procedures," said Paul Re, M.D., Chief of Orthopedics at Emerson Hospital,
 Concord, MA and co-inventor of the Stratis ST system.  "I am finding that the
 fixation is stronger than anything I've used previously."
     Scandius BioMedical launched the Stratis ST system in early December at
 the Arthroscopy Association of North America (AANA) meeting, held in Palm
 Springs, California.  The meeting draws surgeons focused on Arthroscopic
 Sports Medicine, offering a great opportunity for those looking to see new and
 innovative technologies, such as the Stratis ST system.
     "The Stratis ST system's design is intuitive, the measurements required
 are minimal and the instrumentation is designed such that it leads you to a
 consistent end result each time," said Jim Vailas, M.D., Bedford Ambulatory
 Surgery Center, Bedford, NH and Chairman of the Clinical Advisory Board at
 Scandius.  "As I use the Stratis ST system I can see that it will enable me to
 reduce the amount of time it takes for me to complete ACL repairs."
     By using the Stratis ST system, physicians can address the current
 challenges associated with Soft Tissue ACL reconstruction and provide an
 alternative in an area where advances in arthroscopy are needed by surgeons
 and patients alike.  For instance, the Stratis ST system addresses the desire
 to achieve aperture fixation in the knee joint and greater compression of the
 graft in the femoral tunnel.  The Stratis ST system enables physicians to
 overcome obstacles associated with traditional Soft Tissue ACL surgery.
     The company's patented technology consists of an instrument set and a
 femoral fixation implant available in 8mm, 9mm, 10mm diameters, as well as
 25mm and 35mm lengths.
     The implants are available in bio-absorbable and non-absorbable polymer
     "The Stratis ST system is an innovative technology solution that was
 developed to fill the unmet surgical and clinical needs of arthroscopic
 surgeons," said Mark A. Johanson, Founder, President and CEO of Scandius
 BioMedical.  "The launch of the Stratis ST system is a significant event for
 Scandius as we build our presence in the orthopedic sports medicine arena."
     Emerson Hospital and Bedford Ambulatory Surgery Center are the facilities
 where initial surgeries have been successfully performed and have served as a
 resource for training and educational support for launch of the Stratis ST
     Scandius BioMedical, Inc. is a privately held medical device company that
 designs, manufactures and markets products for the orthopedic sports medicine
 market.  The company was founded in 2000 and is focused on accelerating
 innovative solutions for minimally invasive orthopedic sports medicine
 procedures.  Current focus is on arthroscopic soft tissue ACL reconstruction,
 with future development addressing the areas of articular cartilage, meniscal
 repair and other soft tissue sports-related joint injuries.  For more
 information please visit us at

SOURCE Scandius BioMedical, Inc.